Recent advances in the molecular prognostication of meningiomas.
anaplastic
atypical
cytogenetics
epigenetics
genomics
meningioma
methylation
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
04
2022
accepted:
17
11
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
Meningiomas are the most common primary intracranial neoplasm. While traditionally viewed as benign, meningiomas are associated with significant patient morbidity, and certain meningioma subgroups display more aggressive and malignant behavior with higher rates of recurrence. Historically, the risk stratification of meningioma recurrence has been primarily associated with the World Health Organization histopathological grade and surgical extent of resection. However, a growing body of literature has highlighted the value of utilizing molecular characteristics to assess meningioma aggressiveness and recurrence risk. In this review, we discuss preclinical and clinical evidence surrounding the use of molecular classification schemes for meningioma prognostication. We also highlight how molecular data may inform meningioma treatment strategies and future directions.
Identifiants
pubmed: 36686824
doi: 10.3389/fonc.2022.910199
pmc: PMC9845914
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
910199Informations de copyright
Copyright © 2023 Wang, Haddad, Young, Morshed, Wu, Salha, Butowski and Aghi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Genet. 2013 Mar;45(3):295-8
pubmed: 23377182
Science. 2013 Feb 22;339(6122):959-61
pubmed: 23348503
Cell Commun Signal. 2017 Sep 18;15(1):34
pubmed: 28923059
Nat Rev Genet. 2012 Oct;13(10):679-92
pubmed: 22945394
J Neurooncol. 2019 Dec;145(3):449-459
pubmed: 31729637
J Neurosurg. 2017 Aug;127(2):438-444
pubmed: 27885953
Neuro Oncol. 2022 Jan 5;24(1):101-113
pubmed: 34015129
J Natl Cancer Inst. 2015 Dec 13;108(5):
pubmed: 26668184
Nat Commun. 2019 Mar 29;10(1):1425
pubmed: 30926782
Science. 2013 Feb 22;339(6122):957-9
pubmed: 23348506
Cancers (Basel). 2019 Oct 24;11(11):
pubmed: 31652973
Neurol Med Chir (Tokyo). 2015;55(1):14-27
pubmed: 25744347
Neuro Oncol. 2012 Aug;14(8):1090-6
pubmed: 22711605
Clin Cancer Res. 2003 Oct 1;9(12):4443-51
pubmed: 14555517
Acta Neuropathol. 2018 Jun;135(6):955-963
pubmed: 29627952
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
pubmed: 13406590
Mol Med. 2010 Jul-Aug;16(7-8):262-70
pubmed: 20386868
Oncogene. 2003 May 29;22(22):3424-30
pubmed: 12776194
Neurosurg Focus. 2011 May;30(5):E6
pubmed: 21529177
Oncogene. 2013 Sep 5;32(36):4264-72
pubmed: 23045274
Neurosurg Focus. 2013 Dec;35(6):E5
pubmed: 24289130
Int J Cancer. 2003 Feb 10;103(4):483-8
pubmed: 12478663
Acta Neuropathol. 2010 Sep;120(3):297-304
pubmed: 20644945
Sci Adv. 2022 Feb 4;8(5):eabm6247
pubmed: 35108039
J Neurosci Res. 1998 Feb 1;51(3):403-15
pubmed: 9486775
Cancer Res. 2021 Aug 15;81(16):4218-4229
pubmed: 34215617
J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86
pubmed: 15099018
J Neurooncol. 2021 Sep;154(2):237-246
pubmed: 34350560
Acta Neuropathol Commun. 2020 Jun 9;8(1):82
pubmed: 32517746
J Clin Oncol. 2021 Dec 1;39(34):3839-3852
pubmed: 34618539
Oncol Lett. 2014 Jun;7(6):2019-2022
pubmed: 24932282
Science. 2013 Mar 1;339(6123):1077-80
pubmed: 23348505
Brain Tumor Pathol. 2016 Oct;33(4):237-247
pubmed: 27624470
Acta Neuropathol Commun. 2020 Oct 21;8(1):171
pubmed: 33087175
J Neurooncol. 2010 Sep;99(3):379-91
pubmed: 20809251
J Natl Cancer Inst. 2017 Mar 1;109(3):1-4
pubmed: 28376212
Sci Rep. 2020 Jul 28;10(1):12563
pubmed: 32724039
Biochim Biophys Acta. 2007 Apr;1768(4):901-12
pubmed: 17094938
Sci Rep. 2016 Oct 20;6:35743
pubmed: 27760993
Gene. 2017 May 5;611:27-37
pubmed: 28237823
Neuro Oncol. 2017 Aug 01;19(8):1088-1096
pubmed: 28482067
Nat Commun. 2017 Feb 14;8:14433
pubmed: 28195122
Lancet Neurol. 2006 Dec;5(12):1045-54
pubmed: 17110285
Acta Neuropathol Commun. 2020 Apr 3;8(1):41
pubmed: 32245394
J Neurosci. 1997 Apr 1;17(7):2376-82
pubmed: 9065498
Cancer Genet. 2015 Apr;208(4):107-14
pubmed: 25857641
Nat Genet. 2013 Mar;45(3):285-9
pubmed: 23334667
Brain Pathol. 2014 Mar;24(2):184-9
pubmed: 24261697
Biochem Biophys Res Commun. 2003 Aug 22;308(2):251-6
pubmed: 12901861
Acta Neuropathol. 2021 Feb;141(2):281-290
pubmed: 33319313
Am J Clin Oncol. 2009 Feb;32(1):73-85
pubmed: 19194129
Mol Pathol. 2001 Oct;54(5):300-6
pubmed: 11577171
Nature. 2021 Sep;597(7874):119-125
pubmed: 34433969
World Neurosurg. 2017 Jan;97:635-644.e8
pubmed: 27713063
J Med Genet. 2011 Feb;48(2):93-7
pubmed: 20930055
J Neurosurg. 2004 Jun;100(6):1002-13
pubmed: 15200115
Neuro Oncol. 2006 Jan;8(1):27-37
pubmed: 16443945
Cell Rep. 2018 Mar 27;22(13):3672-3683
pubmed: 29590631
Neuro Oncol. 2016 May;18(5):649-55
pubmed: 26826201
Lancet Oncol. 2017 May;18(5):682-694
pubmed: 28314689
Br J Cancer. 2006 Feb 27;94(4):455-9
pubmed: 16449998
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21715-21726
pubmed: 31591222
Neuro Oncol. 2021 Aug 2;23(8):1273-1281
pubmed: 33367841
Neuro Oncol. 2017 Mar 1;19(3):345-351
pubmed: 28082415
Nat Commun. 2020 Sep 23;11(1):4803
pubmed: 32968068
Clin Cancer Res. 2005 Jun 1;11(11):4074-82
pubmed: 15930342
Am J Hum Genet. 2012 Sep 7;91(3):520-6
pubmed: 22958902
NPJ Genom Med. 2017;2:
pubmed: 28713588
J Med Genet. 2022 Jun 29;:
pubmed: 35768194
Cell Death Discov. 2021 Nov 13;7(1):352
pubmed: 34775479
Drug Metab Dispos. 2013 Apr;41(4):923-31
pubmed: 23298861
J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37
pubmed: 17077355
Oncol Rep. 2013 Jan;29(1):283-7
pubmed: 23128672
Cancer. 2004 May 15;100(10):2246-52
pubmed: 15139071
Oncotarget. 2014 Mar 30;5(6):1515-25
pubmed: 24722048
Nat Genet. 2022 May;54(5):649-659
pubmed: 35534562
Acta Neuropathol. 2017 Mar;133(3):431-444
pubmed: 28130639
Future Oncol. 2018 Sep;14(21):2161-2177
pubmed: 30084265
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
J Neurosurg. 2016 Sep;125(3):525-35
pubmed: 26771848
Neuro Oncol. 2022 May 4;24(5):796-808
pubmed: 34508644
Neuro Oncol. 2018 Nov 12;20(12):1584-1593
pubmed: 30010853
Oncogene. 2004 Jan 15;23(2):395-402
pubmed: 14724568
J Neuropathol Exp Neurol. 2000 Jul;59(7):614-20
pubmed: 10901233
J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36
pubmed: 11398839
Neuro Oncol. 2004 Oct;6(4):290-9
pubmed: 15494096
J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):378-387
pubmed: 32041819
Nature. 2007 Jul 26;448(7152):439-44
pubmed: 17611497
J Med Genet. 2006 Mar;43(3):285-7
pubmed: 15980114
Oncotarget. 2019 May 28;10(37):3506-3517
pubmed: 31191822
Front Immunol. 2020 Nov 19;11:589929
pubmed: 33329574
Acta Neuropathol. 2013 Mar;125(3):351-8
pubmed: 23404370
Oncogene. 1993 Jul;8(7):1721-9
pubmed: 8390035
Cancer Res. 2005 Apr 1;65(7):2746-54
pubmed: 15805274
J Mol Cell Biol. 2017 Aug 1;9(4):315-324
pubmed: 28651379
Case Rep Genet. 2019 Jul 28;2019:9650184
pubmed: 31485359
Genes Chromosomes Cancer. 1997 Dec;20(4):419-24
pubmed: 9408760
Sci Rep. 2018 Jan 22;8(1):1303
pubmed: 29358593
BMC Genomics. 2007 Jan 12;8:16
pubmed: 17222329
Ann Genet. 1998;41(3):164-75
pubmed: 9833072
Neuro Oncol. 2018 Jul 5;20(8):1122-1132
pubmed: 29186568
Nat Genet. 2016 Oct;48(10):1253-9
pubmed: 27548314
Nat Genet. 2002 Jul;31(3):306-10
pubmed: 12068298
Oncogene. 2004 Feb 12;23(6):1291-9
pubmed: 14647409